Aptamer Binding and Neutralization of β 1-Adrenoceptor Autoantibodies: Basics and a Vision of Its Future in Cardiomyopathy Treatment

Trends in Cardiovascular Medicine

Volumn 21, Issue 6, 2011, Pages 177-182

  Haberland, Annekathrin ^a   Wallukat, Gerd ^b   Schimke, Ingolf ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; AUTOANTIBODY; BETA 1 ADRENERGIC RECEPTOR; DOUBLE STRANDED DNA; DOUBLE STRANDED RNA; G PROTEIN COUPLED RECEPTOR; NEUTRALIZING ANTIBODY; OLIGONUCLEOTIDE; RECEPTOR ANTIBODY; SECOND EXTRACELLULAR RECEPTOR LOOP OF BETA 1 ADRENERGIC RECEPTOR; SINGLE STRANDED DNA; SINGLE STRANDED RNA; UNCLASSIFIED DRUG;

APHERESIS; BINDING AFFINITY; CARDIOMYOPATHY; CHAGAS DISEASE; CONGESTIVE CARDIOMYOPATHY; DNA SEQUENCE; HUMAN; IMMUNOGENICITY; NONHUMAN; PATHOGENESIS; PERIPARTUM CARDIOMYOPATHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW; RNA SEQUENCE;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANIMALS; APTAMERS, NUCLEOTIDE; AUTOANTIBODIES; BLOOD COMPONENT REMOVAL; CARDIOMYOPATHIES; HUMANS; MICE; PROTEIN BINDING; RATS; RECEPTORS, ADRENERGIC, BETA-1;

EID: 84863877617     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.05.006     Document Type: Review

References (44)

1. Carothers J.M., Oestreich S.C., Davis J.H., Szostak J.W. Informational complexity and functional activity of RNA structures. J Am Chem Soc 2004, 126:5130-5137.
2. Carothers J.M., Oestreich S.C., Szostak J.W. Aptamers selected for higher-affinity binding are not more specific for the target ligand. J Am Chem Soc 2006, 128:7929-7937.
3. Dandel M., Wallukat G., Potapov E., Hetzer R. Role of β(1)-adrenoceptor autoantibodies in the pathogenesis of dilated cardiomyopathy. Immunobiology 2011, 217:511-520.
4. Dandel M., Wallukat G., Englert A., et al. Longterm outcome after beta1 adrenoceptor autoantibody removal in heart transplant candidate with dilated cardiomyopathy. J Am Col Cardiol 2011, 57:E194. Abstr.
5. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
6. Ewert R., Reinthaler M., Herda L.R., Felix S.B. Randomized, prospective investigation on the effects of immunoadsorption on pulmonary vascular resistance in patients with pulmonary hypertension 2010, National Institutes of Health, Bethesda, MD, Publication No.NCT01126411. http://clinicaltrials.gov.
7. Ewert S.B., Reinthaler C.R., Herda A., et al. Immunoadsorption and immunoglobulin substitution for heart failure after myocardial infarction 2008, National Institutes of Health, Bethesda, MD, Publication No.NCT00738517. http://clinicaltrials.gov.
8. Forster O. Peripartum cardiomyopathy: An autoimmune disease? [dissertation] 2007, University of the Witwatersrand, Johannesburg.
9. Fu L.X., Magnusson Y., Bergh C.H. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1993, 91:1964-1968.
10. Gouldson P.R., Higgs C., Smith R.E., et al. Dimerization and domain swapping in G-protein-coupled receptors: A computational study. Neuropsychopharmacology 2000, 23:S60-S77.
11. Haberland A., Wallukat G., Dahmen C., et al. Aptamer-based immunotherapy. From Prediction to Prevention of Autoimmune Diseases 2011, 466-474. Pabst Science, Lengerich, Germany. K. Conrad (Ed.).
12. Haberland A., Wallukat G., Dahmen C., et al. Aptamer neutralization of beta1-adrenoceptor autoantibodies isolated from patients with cardiomyopathies. Circ Res 2011, 109:986-992.
13. Jacoby E., Bouhelal R., Gerspacher M., Seuwen K. The 7TM G-protein-coupled receptor target family. ChemMedChem 2006, 1:760-782.
14. Jahns R., Boivin V., Hein L., et al. Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004, 113:1419-1429.
15. 1-adrenergic receptor antibodies 2005, WO 2006 / 103101 A2.
16. Jahns R., Boivin V., Lohse M.J. Beta(1)-adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy. Trends Cardiovasc Med 2006, 16:20-24.
17. Keefe A.D., Pai S., Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010, 9:537-550.
18. Keefe A.D., Schaub R.G. Aptamers as candidate therapeutic for cardiovascular indications. Curr Opin Pharmacol 2008, 8:147-152.
19. Kulbachinskiy A.V. Methods for selection of aptamers to protein targets. Biochemistry (Moscow) 2007, 72:1505-1518.
20. Labovsky V., Smulski C.R., Gómez K., et al. Anti-beta1-adrenergic receptor autoantibodies in patients with chronic Chagas heart disease. Clin Exp Immunol 2007, 148:440-449.
21. 1 receptor antibody cyclopeptide, in Five different strengths in healthy male volunteers 2009, National Institutes of Health, Bethesda, MD, Publication No.NCT01043146. http://clinicaltrials.gov.
22. Lee S.W., Sullenger B.A. Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes. J Exp Med 1996, 184:315-324.
23. Lee S.W., Sullenger B.A. Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nat Biotechnol 1997, 15:41-45.
24. Marquis J.K., Grindel J.M. Toxicological evaluation of oligonucleotide therapeutics. Curr Opin Mol Ther 2000, 2:258-263.
25. Matsui S., Fu M.L., Hayase M., et al. Active immunization of combined beta1-adrenoceptor and M2-muscarinic receptor peptides induces cardiac hypertrophy in rabbits. J Card Fail 1999, 5:246-254.
26. Mijares A., Lebesgue D., Wallukat G., Hoebeke J. From agonist to antagonist: Fab fragments of an agonist-like monoclonal anti-beta(2)-adrenoceptor antibody behave as antagonists. Mol Pharmacol 2000, 58:373-379.
27. Munoz Saravia S.G., Haberland A., Bartel S., et al. Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon: Their potential impact for early risk assessment in asymptomatic Chagas' patients. J Am Coll Cardiol 2010, 56:526-527.
28. Munoz-Saravia S.G., Haberland A., Wallukat G., Schimke I. Chronic Chagas' heart disease: From pathogenesis to treatment regimes. Appl Cardiopulm Pathophysiol 2012, 16:55-81.
29. Nikolaev V.O., Boivin V., Störk S., et al. A novel fluorescence method for the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. J Am Coll Cardiol 2007, 50:423-431.
30. Nitsche A., Kurth A., Dunkhorst A., et al. One-step selection of vaccinia virus-binding DNA aptamers by Monolex. BMC Biotechnol 2007, 7:48.
31. Noma T., Ikebukuro K., Sode K., et al. A screening method for DNA aptamers that bind to a specific, unidentified protein in tissue samples. Biotechnol Lett 2006, 28:1377-1381.
32. Rimmele M. Nucleic acid aptamers as tools and drugs: Recent developments. ChemBioChem 2003, 4:963-971.
33. Rönspeck W., Kunze R., Wallukat G. Peptide gegen DCM hervorrufende Autoantikörper 2001, EP 1086954 A1.
34. Schimke I., Haberland A., Kage A., et al. Aptamers that inhibit interaction between antibody and 2nd extracellular loop of human beta1-adrenergic receptor 2012, WO/2012/000889.
35. Sullenger B.A., Gallardo H.F., Ungers G.E., Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 1990, 63:601-608.
36. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
37. Vater A., Jarosch F., Buchner K., Klussmann S. Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: Tailored-SELEX. Nucleic Acids Res 2003, 31:e130.
38. Wallukat G., Haberland A., Berg S., et al. The first aptamer-apheresis column specifically for clearing blood of beta1-receptor autoantibodies: a successful proof of principle using autoantibody positive SHR rats. Circ J 2012.
39. Wallukat G., Morwinski M., Kowal K., et al. Autoantibodies against the beta-adrenergic receptor in human myocarditis and dilated cardiomyopathy: Beta-adrenergic agonism without desensitization. Eur Heart J 1991, 12(Suppl D):178-181.
40. Wallukat G., Muñoz Saravia S.G., Haberland A., et al. Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon: Their potential impact for early risk assessment in asymptomatic Chagas' patients. J Am Coll Cardiol 2010, 55:463-468.
41. Wallukat G., Nissen E., Müller J., et al. The pathophysiological role of autoantibodies directed to G-protein coupled receptors and therapeutic strategies of antibody removal. G-Protein Coupled Receptors and Autoantibodies 2002, 7-47. Pabst Science Publishers, Lengerich, Germany. R. Brinckmann, R. Kunze (Eds.).
42. Xia Y., Kellems R.E. Receptor-activating autoantibodies and disease: Preeclampsia and beyond. Expert Rev Clin Immunol 2011, 7:659-674.
43. Yoshikawa T., Baba A., Nagatomo Y. Autoimmune mechanisms underlying dilated cardiomyopathy. Circ J 2009, 73:602-607.
44. Zuo L., Bao H., Tian J., et al. Long-term active immunization with a synthetic peptide corresponding to the second extracellular loop of β1-adrenoceptor induces both morphological and functional cardiomyopathic changes in rats. Int J Cardiol 2011, 149:89-94.